The abstract is read at the publisher; the summary is JClub's.
Midkine (MDK) is the only gene passing FDR correction for pancreatic ductal adenocarcinoma risk, with an inverse-variance-weighted odds ratio of 1.51 (95% CI 1.19–1.91).
- Why it matters: PDAC lethality is linked to an immunosuppressive tumor microenvironment, but MDK’s causal role in disease risk and the responsible cell types were unclear.
- What they did: The study combined cis-eQTL Mendelian randomization (GTEx pancreas, n = 328; FinnGen PDAC, 1,252 cases) with MOFA (TCGA-PAAD, n = 149), ssGSEA, cross-species single-cell RNA-seq, and DepMap CRISPR dependency screening.
- The result: MDK localized to a MOFA factor tied to tertiary lymphoid structure yet negatively correlated with dendritic cells and macrophages, and single-cell and DepMap analyses support stromal production (cancer-associated fibroblasts and endothelial cells) rather than tumor-cell intrinsic fitness.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.